Display options
Cite
Song F, Poljak A, Kochan NA, et al. Plasma protein profiling of Mild Cognitive Impairment and Alzheimer's disease using iTRAQ quantitative proteomics. Proteome Sci. 2014;12(1):5doi: 10.1186/1477-5956-12-5.
Song, F., Poljak, A., Kochan, N. A., Raftery, M., Brodaty, H., Smythe, G. A., & Sachdev, P. S. (2014). Plasma protein profiling of Mild Cognitive Impairment and Alzheimer's disease using iTRAQ quantitative proteomics. Proteome science, 12(1), 5. https://doi.org/10.1186/1477-5956-12-5
Song, Fei, et al. "Plasma protein profiling of Mild Cognitive Impairment and Alzheimer's disease using iTRAQ quantitative proteomics." Proteome science vol. 12,1 (2014): 5. doi: https://doi.org/10.1186/1477-5956-12-5
Song F, Poljak A, Kochan NA, Raftery M, Brodaty H, Smythe GA, Sachdev PS. Plasma protein profiling of Mild Cognitive Impairment and Alzheimer's disease using iTRAQ quantitative proteomics. Proteome Sci. 2014 Jan 17;12(1):5. doi: 10.1186/1477-5956-12-5. PMID: 24433274; PMCID: PMC3898732.
Copy Download .nbib Format: NLM
Share it on

Proteome Sci. 2014 Jan 17;12(1):5. doi: 10.1186/1477-5956-12-5.

Plasma protein profiling of Mild Cognitive Impairment and Alzheimer's disease using iTRAQ quantitative proteomics.

Proteome science

Fei Song, Anne Poljak, Nicole A Kochan, Mark Raftery, Henry Brodaty, George A Smythe, Perminder S Sachdev

Affiliations

  1. Bioanalytical Mass Spectrometry Facility, University of New South Wales, Sydney, Australia. [email protected].

PMID: 24433274 PMCID: PMC3898732 DOI: 10.1186/1477-5956-12-5

Abstract

BACKGROUND: With the promise of disease modifying treatments, there is a need for more specific diagnosis and prognosis of Alzheimer's disease (AD) and mild cognitive impairment (MCI). Plasma biomarkers are likely to be utilised to increase diagnostic accuracy and specificity of AD and cognitive decline.

METHODS: Isobaric tags (iTRAQ) and proteomic methods were used to identify potential plasma biomarkers of MCI and AD. Relative protein expression level changes were quantified in plasma of 411 cognitively normal subjects, 19 AD patients and 261 MCI patients. Plasma was pooled into 4 groups including normal control, AD, amnestic single and multiple domain MCI (aMCI), and nonamnestic single and multiple domain MCI (nMCI). Western-blotting was used to validate iTRAQ data. Integrated function and protein interactions were explored using WEB based bioinformatics tools (DAVID v6.7 and STRING v9.0).

RESULTS: In at least two iTRAQ replicate experiments, 30 proteins were significantly dysregulated in MCI and AD plasma, relative to controls. These proteins included ApoA1, ApoB100, complement C3, C4b-binding protein, afamin, vitamin D-binding protein precursor, isoform 1 of Gelsolin actin regulator, Ig mμ chain C region (IGHM), histidine-rich glycoprotein and fibrinogen β and γ chains. Western-blotting confirmed that afamin was decreased and IGHM was increased in MCI and AD groups. Bioinformatics results indicated that these dysregulated proteins represented a diversity of biological processes, including acute inflammatory response, cholesterol transport and blood coagulation.

CONCLUSION: These findings demonstrate that expression level changes in multiple proteins are observed in MCI and AD plasma. Some of these, such as afamin and IGHM, may be candidate biomarkers for AD and the predementia condition of MCI.

References

  1. J Cell Mol Med. 2009 Sep;13(9A):2911-25 - PubMed
  2. Biochemistry. 2002 Dec 10;41(49):14532-8 - PubMed
  3. Dement Geriatr Cogn Disord. 1998;9 Suppl 2:20-6 - PubMed
  4. Consult Pharm. 2010 Jul;25(7):440-50 - PubMed
  5. Mol Immunol. 2008 Aug;45(13):3649-60 - PubMed
  6. Mol Immunol. 2004 Jan;40(11):785-93 - PubMed
  7. Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21812-7 - PubMed
  8. Expert Opin Ther Targets. 2010 Jun;14(6):585-92 - PubMed
  9. Prenat Diagn. 2008 Aug;28(8):691-8 - PubMed
  10. J Alzheimers Dis. 2012;28(2):369-75 - PubMed
  11. Int Psychogeriatr. 2010 Dec;22(8):1248-64 - PubMed
  12. Arch Neurol. 2010 Jul;67(7):819-25 - PubMed
  13. Brain. 2006 Nov;129(Pt 11):3042-50 - PubMed
  14. N Engl J Med. 1997 Apr 24;336(17):1216-22 - PubMed
  15. Neurol Clin. 2007 Aug;25(3):577-609, v - PubMed
  16. Nat Med. 2007 Nov;13(11):1359-62 - PubMed
  17. Biogerontology. 2008 Dec;9(6):381-9 - PubMed
  18. Arch Neurol. 2010 Jul;67(7):867-72 - PubMed
  19. Prog Neurobiol. 2013 Feb-Mar;101-102:1-17 - PubMed
  20. PLoS One. 2012;7(6):e34078 - PubMed
  21. J Biol Chem. 2010 Nov 19;285(47):36958-68 - PubMed
  22. Proteomics Clin Appl. 2007 May;1(5):506-12 - PubMed
  23. J Intern Med. 2004 Sep;256(3):183-94 - PubMed
  24. JAMA. 2002 Jun 26;287(24):3223-9 - PubMed
  25. Nat Genet. 2009 Oct;41(10):1088-93 - PubMed
  26. World Psychiatry. 2008;7(2):72-8 - PubMed
  27. Springer Semin Immunopathol. 2005 Mar;26(4):485-503 - PubMed
  28. Nat Protoc. 2009;4(1):44-57 - PubMed
  29. J Proteome Res. 2008 Jul;7(7):2952-8 - PubMed
  30. Proteomics. 2004 Jan;4(1):244-56 - PubMed
  31. J Proteome Res. 2005 May-Jun;4(3):889-99 - PubMed
  32. J Proteome Res. 2010 Feb 5;9(2):653-63 - PubMed
  33. J Neurosci. 2004 Jul 14;24(28):6277-82 - PubMed
  34. Neurobiol Aging. 2004 Sep;25(8):1023-32 - PubMed
  35. J Biol Chem. 2011 Sep 2;286(35):30314-30323 - PubMed
  36. Int Immunopharmacol. 2007 Dec 20;7(14):1888-99 - PubMed
  37. Arch Neurol. 2002 Jun;59(6):972-6 - PubMed
  38. JAMA. 2002 Jun 26;287(24):3230-7 - PubMed
  39. Reprod Biomed Online. 2011 Aug;23(2):213-9 - PubMed
  40. Biochem Soc Trans. 2011 Aug;39(4):898-901 - PubMed
  41. Nutr Neurosci. 2005 Feb;8(1):21-9 - PubMed
  42. Brain Res Rev. 2009 Oct;61(2):69-80 - PubMed
  43. Autoimmun Rev. 2008 May;7(5):391-7 - PubMed
  44. Neurobiol Aging. 2012 Feb;33(2):433.e11-20 - PubMed
  45. J Neurochem. 2009 Feb;108(3):707-18 - PubMed
  46. J Alzheimers Dis. 2010;21(2):585-96 - PubMed
  47. Proc Natl Acad Sci U S A. 2009 May 5;106(18):7501-6 - PubMed
  48. Am Fam Physician. 2011 Jun 15;83(12):1425-30 - PubMed
  49. Biol Psychiatry. 2003 Jul 15;54(2):136-41 - PubMed
  50. J Proteome Res. 2010 Jan;9(1):352-8 - PubMed
  51. Clin Chim Acta. 1995 Aug 14;239(2):209-11 - PubMed
  52. Proteomics. 2010 Apr;10(8):1621-33 - PubMed
  53. J Neurosci Res. 2011 Apr;89(4):576-84 - PubMed
  54. Autoimmun Rev. 2008 Jun;7(6):415-20 - PubMed
  55. Nucleic Acids Res. 2009 Jan;37(1):1-13 - PubMed
  56. Neurology. 1984 Jul;34(7):939-44 - PubMed
  57. Mol Neurodegener. 2011 Nov 23;6:79 - PubMed
  58. Int J Clin Pract. 2008 Jul;62(7):1070-5 - PubMed
  59. Clin Cancer Res. 2007 Dec 15;13(24):7370-9 - PubMed
  60. Biochem Biophys Res Commun. 2009 Feb 6;379(2):267-71 - PubMed
  61. Exp Gerontol. 2002 Jul;37(7):943-8 - PubMed
  62. Br J Nutr. 2010 Mar;103(5):652-62 - PubMed
  63. Biochem Biophys Res Commun. 1992 Jul 15;186(1):461-6 - PubMed
  64. Neurobiol Dis. 2005 Nov;20(2):574-82 - PubMed
  65. J Intern Med. 2004 Sep;256(3):240-6 - PubMed
  66. Proteomics Clin Appl. 2008 Apr;2(4):467-77 - PubMed
  67. Stroke. 2005 Dec;36(12):2637-41 - PubMed
  68. BMC Cancer. 2008 Jan 28;8:25 - PubMed
  69. Eur J Clin Invest. 2002 May;32(5):360-71 - PubMed
  70. J Biomed Biotechnol. 2010;2010:952047 - PubMed
  71. Nutrition. 2001 Oct;17(10):809-14 - PubMed
  72. J Exp Med. 2007 Aug 6;204(8):1999-2008 - PubMed
  73. Nucleic Acids Res. 2009 Jan;37(Database issue):D412-6 - PubMed
  74. Acta Neuropathol. 1995;89(4):356-62 - PubMed

Publication Types